Navigation Links
ANA598 Demonstrates SVR12 in 100% of First Group of HCV Patients Randomized to Stop All Treatment at Week 24
Date:7/29/2010

ANA598 demonstrated potent antiviral activity, including median end-of-treatment declines in viral load ranging from 2.4 to 2.9 log10 in a three day monotherapy study in treatment-naïve genotype 1 patients.  ANA598 has also demonstrated a very favorable resistance profile.

Anadys has completed two long-term chronic toxicology studies of ANA598 (26 weeks duration in rats and 39 weeks duration in monkeys).  The No Observed Adverse Effect Level, or NOAEL, is 1000 mg/kg, the highest dose tested, in both the rat and monkey.  The completed toxicology studies support the ongoing Phase II clinical study as well as future clinical studies of longer duration.

Anadys has presented in vitro data supporting the use of ANA598 in combination with interferon-alpha as well as with other anti-HCV agents currently in development that act through diverse mechanisms.  In particular, data has shown that ANA598 is synergistic in vitro with interferon-alpha as well as representative HCV protease inhibitors, polymerase inhibitors, NS5A inhibitors and cyclophilin inhibitors.  In vitro combination treatment at clinically relevant concentrations of ANA598 with interferon-alpha as well as DAAs from multiple classes results in clearance of HCV RNA from cells rather than selection of resistant isolates.  Furthermore, ANA598 retains full activity in vitro against mutations conferring resistance to protease inhibitors, nucleoside polymerase inhibitors and non-nucleoside polymerase inhibitors that act at binding sites distinct from that of ANA598, while protease and nucleoside polymerase inhibitors retain full activity in vitro against mutations conferring resistance to ANA598.

ANA598 has received Fast Track Status from the FDA for the treatment of chronic hepatitis C.

Safe Harbor Statement


'/>"/>
SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
6. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
7. ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
8. ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
9. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
10. ANA598 Demonstrates Positive 4-Week Results at 200 mg BID
11. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , Germany , and ... , Exclusive global license from ... SF3B1 mutations, including next-generation sequencing (NGS) gene panels, for ... be targeted by new test, indicate favorable prognosis for ... QIAGEN sees potential for developing companion diagnostics ...
(Date:7/24/2014)... CITY, Calif., July 24, 2014  Abaxis, Inc. (NasdaqGS: ... point-of-care blood analysis systems, today reported financial results for ... First quarter overview: , Revenues of $47.5 ... , Diluted EPS of $0.21, up 50% over last ... Medical market revenues of $7.2 million, up 20% over ...
(Date:7/24/2014)... MOUNTAIN VIEW, Calif. , July 24, 2014 /PRNewswire/ ... that it will release its second quarter 2014 financial ... 31, 2014. In conjunction with the release, the ... community at 5:00 p.m. Eastern Time on ... results of the quarter and other business developments. ...
Breaking Medicine Technology:QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 2QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 3QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 4QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 2Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 4Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 6Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 7Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 8Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 9Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 10Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 11
... Heska Corporation (Nasdaq: HSKA ; "Heska" or ... quarter ended September 30, 2009. , (Logo: ... the most profitable quarter this year and the financial ... flow from our operations has allowed us to reduce ...
... Lumenis Ltd., a global developer, manufacturer and seller of ... ophthalmic applications, announced that on September 30th, 2009 the ... PolyScope Flexible Endoscope can now be sold in the ... indicated in flexible endoscopic procedures for diagnostic and therapeutic ...
Cached Medicine Technology:Heska Announces Q309 Results 2Heska Announces Q309 Results 3Heska Announces Q309 Results 4Heska Announces Q309 Results 5Lumenis Receives 510K Clearance for the PolyScope Disposable Flexible Endoscope 2Lumenis Receives 510K Clearance for the PolyScope Disposable Flexible Endoscope 3Lumenis Receives 510K Clearance for the PolyScope Disposable Flexible Endoscope 4
(Date:7/26/2014)... July 26, 2014 The birth control ... Mirena IUD contraceptive of new legal information on the ... showing the number of lawsuits pending for July alleging ... free resource for those using popular prescription drugs and ... recalls, studies and legal news all in one place, ...
(Date:7/25/2014)... In recent years, men have become more ... the symptoms associated with age-related testosterone decline. Amid concerns about ... new case study from Renew Man helps to ... using bioidentical hormones. , The case study centers around ... found himself beginning to feel the effects of age-related hormonal ...
(Date:7/25/2014)... As reported by the New Orleans Advocate in ... (7/3), the state of Louisiana has recently seen a large ... cocaine. Officials believe the increase is due to a misconception ... marijuana. However, both doctors and police confirm that that belief ... call it “poison,” doctors have acknowledged that the Louisiana Poison ...
(Date:7/25/2014)... Sport Court® provided and ... Nike National Invitational Tournament (NIT) in Chicago at ... National Tournament (USJN) in Washington D.C. at the ... these prestigious national tournaments included 44 Sport Court Maple ... playing surface at McCormick Place for the NIT, and ...
(Date:7/25/2014)... TX (PRWEB) July 25, 2014 The ... Family Fun Fest on Sunday, July 27 at Discovery ... franchises include Memorial, Copperfield, Katy, Pearland, Friendswood, Spring, The ... in The Heights. , “We’re thrilled to be ... year,” said Heather Belcher who owns the Sugarland-Missouri City ...
Breaking Medicine News(10 mins):Health News:DrugNews Adds Latest Court Updates on Mirena IUD Lawsuits 2Health News:New Case Study Highlights Effectiveness of Testosterone Therapy in Fighting Weight Gain and Fatigue 2Health News:New Case Study Highlights Effectiveness of Testosterone Therapy in Fighting Weight Gain and Fatigue 3Health News:Louisiana Recognizes Dangers of Synthetic Marijuana 2Health News:Sport Court Provides All Sports Flooring for Basketball Events in Chicago and Washington D.C. 2Health News:The Little Gym of Houston to Attend Houston Family Magazine’s Family Fun Fest 2014 2
... Several years ago, scientists at Beth Israel Deaconess Medical ... regarding the Akt molecular pathway, a popular target for ... protein Akt1 was actively preventing cancer cells ... was actually promoting breast cancer cell migration. And, ...
... be one of the leading causes of oral cancer, ... experimental animals has traditionally been limited to examining the ... rather than on observing the effects of carcinogens that ... completed study conducted collaboratively by Dr. Joseph Guttenplan, a ...
... for building new organs to replace damaged livers, blood vessels ... cells grown in a lab dish to form 3-D shapes ... of Health Sciences and Technology (HST) have come up with ... cells in cubes and arranging them into 3-D structures, just ...
... strong, healthy bones. But new research from North Carolina ... the earliest days of life could have a more ... obesity than previously thought. During an 18-day trial ... levels of bone density and strength in 12 piglets ...
... physical competition, not attraction, was central in winning ... State anthropologist., "There is sexual competition in many ... professor of biological anthropology. Many researchers have ... sexual selection. They thought that people,s mating success ...
... ... (NWS), a leading provider of water conservation and water management services, was recently awarded ... ... 2010 -- National Water Services, Inc. (NWS), a leading provider of ...
Cached Medicine News:Health News:Study identifies 1 of the mechanisms behind breast cancer metastasis 2Health News:NYU College of Dentistry, Penn State develop new model for investigating tobacco/oral cancer link 2Health News:Tissue engineers create a new way to assemble artificial tissues 2Health News:Tissue engineers create a new way to assemble artificial tissues 3Health News:Calcium in early life may prevent obesity later 2Health News:It was brawn over beauty in human mating competition 2Health News:National Water Services, Inc. Receives WBE Certification 2
PDA format of the well-known standard antimicrobial reference....
PDA application providing a complete guide for the diagnosis and management of electrolyte disorders....
Contains the most common procedures from all orthopedic sub-specialties organized by body area....
Consists of the print and PDA versions of Harrison's Manual of Medicine 15th Edition. Provides high-end medical content via PDA....
Medicine Products: